SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Aresu M, Chaudhury M, Diment E, Fuller E, Gordon-Dseagu V, Gunning N, Mindell J, Nicholson S, Ogunbadejo T, Robinson C, Roderick P, Roth M, Shelton N, Tabassum F, Wardle H. Health survey for England – 2009: trend tables. The NHS information centre for health and social care. 2010.
  • 2
    Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 4353.
  • 3
    Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011; 90: 4051.
  • 4
    Vivus Inc. Press Release. New long-term data on QNEXA® show significant and sustained weight loss of greater than 10% over two years. 2010. Available at http://files.shareholder.com/downloads/VVUS/1475992835x0x404069/76148ab7-f72c-4cf4-9246-aadd88909659/SEQUEL_TWO_YEAR_DATA_RELEASE_FINAL.pdf (last accessed 12 April 2012).
  • 5
    Vivus Inc. Press release. FDA Issues complete response letter to Vivus regarding new drug application for QNEXA®. 2010. Available at http://ir.vivus.com/releasedetail.cfm?ReleaseID=524576 (last accessed 12 April 2012).
  • 6
    Orexigen®Therapeutics. Press release. FDA issues complete response to new drug application for Contrave for the management of obesity. 2011. Available at http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1522207&highlight= (last accessed 12 April 2012).
  • 7
    Arena Pharmaceuticals. Press release. FDA issues complete response letter for lorcaserin new drug application. 2010. Available at http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977 (last accessed 12 April 2012).
  • 8
    Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 2011; 164: 124862.
  • 9
    Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 133240.
  • 10
    Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, Chan K, Manners MT, Samad TA, Kennedy JD, Bingham B, Whiteside GT. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010; 39: 14855.
  • 11
    Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 94350.
  • 12
    Vivus. Press release. Vivus resubmits Qnexa NDA to the FDA. 2011. Available at http://ir.vivus.com/releasedetail.cfm?ReleaseID=615313 (last accessed 12 April 2012).
  • 13
    Vivus Inc. Press release. FDA advisory committee recommends approval of Qnexa®. 2012. Available at http://ir.vivus.com/releasedetail.cfm?ReleaseID=650759 (last accessed 12 April 2012).
  • 14
    Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595605.
  • 15
    Orexigen®Therapeutics. Press release. Orexigen and FDA identify a clear and feasible path to approval for Contrave®. 2011. Available at http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1608571&highlight= (last accessed 12 April 2012).
  • 16
    Orexigen® Therapeutics, Inc. Press release. Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave® Outcomes Trial. 2012. Available at http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1608571&highlight= (last accessed 12 April 2012).
  • 17
    Arena Pharmaceuticals. Press release. Arena and Eisai announce results of re-adjudication of rat mammary tumors from lorcaserin carcinogenicity study. 2011. Available at http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=597830 (last accessed 12 April 2012).
  • 18
    Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008; 325: 57787.
  • 19
    Stanley S, Wynne K, Bloom S. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol 2004; 286: G6937.
  • 20
    Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 15961.
  • 21
    Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996; 2: 58993.
  • 22
    Ramsey JJ, Kemnitz JW, Colman RJ, Cunningham D, Swick AG. Different central and peripheral responses to leptin in rhesus monkeys: brain transport may be limited. J Clin Endocrinol Metab 1998; 83: 32305.
  • 23
    Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 9418.
  • 24
    Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 23905.
  • 25
    Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68: 52530.
  • 26
    Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 30411.
  • 27
    Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 1999; 6: 100517.
  • 28
    Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1695706.
  • 29
    De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS. The gut hormones PYY(3-36) and GLP-1(7-36 amide) reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 7006.
  • 30
    Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000; 49: 70917.
  • 31
    Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 1996; 271: 232229.
  • 32
    Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 112631.
  • 33
    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 3947.
  • 34
    Novo Nordisk. Press release. Significant weight loss sustained in obese people treated with liraglutide for one year. 2008. Available at http://www.novonordisk.com/science/Pipeline/liraglutide-press-releases.asp (last accessed 12 April 2012).
  • 35
    Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010; 44: 9049.
  • 36
    Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45: e22.
  • 37
    Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58: 214861.
  • 38
    Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010; 299: E107686.
  • 39
    Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Molck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 147386.
  • 40
    Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; 96: 85360.
  • 41
    Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbaek N, Holst J, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011; 96: 1695702.
  • 42
    Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 424450.
  • 43
    Liu YL, Ford HE, Druce MR, Minnion JS, Field BC, Shillito JC, Baxter J, Murphy KG, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes (Lond) 2010; 34: 171525.
  • 44
    Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 54658.
  • 45
    Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696701.
  • 46
    Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 172936.
  • 47
    Parkinson JR, Chaudhri OB, Kuo YT, Field BC, Herlihy AH, Dhillo WS, Ghatei MA, Bloom SR, Bell JD. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44: 102231.
  • 48
    Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 268795.
  • 49
    Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009; 150: 171222.
  • 50
    Santoprete A, Capito E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S, Veneziano M, Bonelli F, Zhu L, Monteagudo E, Marsh DJ, Sinharoy R, Bianchi E, DPP-I PA. V-resistant, long-acting oxyntomodulin derivatives. J Pept Sci 2011; 17: 27080.
  • 51
    Kerr BD, Flatt PR, Gault VA. D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem Pharmacol 2010; 80: 172735.
  • 52
    Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 225866.
  • 53
    Kokrashvili Z, Mosinger B, Margolskee RF. Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones. Am J Clin Nutr 2009; 90: 822S5S.
  • 54
    Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE, Reeve JR. A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 1989; 10: 797803.
  • 55
    Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49: 13344.
  • 56
    Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292: E10628.
  • 57
    Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311: 9159.
  • 58
    Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005; 146: 87988.
  • 59
    Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129: 14306.
  • 60
    Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 6504.
  • 61
    Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R3946.
  • 62
    Reidelberger RD, Haver AC, Chelikani PK, Buescher JL. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R44958.
  • 63
    Lluis F, Fujimura M, Gomez G, Salva JA, Greeley GH Jr, Thompson JC. [Cellular localization, half-life, and secretion of peptide YY]. Rev Esp Fisiol 1989; 45: 37784.
  • 64
    le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 2008; 45: 935.
  • 65
    Medeiros MD, Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 1994; 134: 208894.
  • 66
    Addison ML, Minnion JS, Shillito JC, Suzuki K, Tan TM, Field BC, Germain-Zito N, Becker-Pauly C, Ghatei MA, Bloom SR, Murphy KG. A role for metalloendopeptidases in the breakdown of the gut hormone, PYY3-36. Endocrinology 2011; 152: 463040.
  • 67
    Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, Mahle CD, Lumb KJ. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 2007; 323: 692700.
  • 68
    DeCarr LB, Buckholz TM, Milardo LF, Mays MR, Ortiz A, Lumb KJ. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett 2007; 17: 19169.
  • 69
    Shechter Y, Tsubery H, Mironchik M, Rubinstein M, Fridkin M. Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett 2005; 579: 243944.
  • 70
    Sainsbury A, Shi YC, Zhang L, Aljanova A, Lin Z, Nguyen AD, Herzog H, Lin S. Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways. Neuropeptides 2010; 44: 2618.
  • 71
    Malaisse-Lagae F, Carpentier JL, Patel YC, Malaisse WJ, Orci L. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis Cell Mol Life Sci 1977; 33: 9157.
  • 72
    Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 398992.
  • 73
    Jesudason DR, Monteiro MP, McGowan BM, Neary NM, Park AJ, Philippou E, Small CJ, Frost GS, Ghatei MA, Bloom SR. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 2007; 97: 4269.
  • 74
    Bellmann-Sickert K, Elling CE, Madsen AN, Little PB, Lundgren K, Gerlach LO, Bergmann R, Holst B, Schwartz TW, Beck-Sickinger AG. Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J Med Chem 2011; 54: 265867.
  • 75
    Tan TM, Field BC, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA, Bloom SR. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2011; 73: 2329.
  • 76
    Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 16359.
  • 77
    Neary NM, McGowan BM, Monteiro MP, Jesudason DR, Ghatei MA, Bloom SR. No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration. Int J Obes (Lond) 2008; 32: 143840.
  • 78
    Pharma TM. Press release. 7TM Pharma obtains patent protection for the use of both obinepitide and TM30339 in the treatment of obesity. 2007. Available at http://www.7tm.com/News/News_Archive.aspx?M=News&PID=45&NewsID=6 (last accessed 12 April 2012).
  • 79
    Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 51207.
  • 80
    Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010; 92: 8107.
  • 81
    Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005; 2: 41933.
  • 82
    Majuru S. Advances in the oral delivery of heparin from solid dosage forms using Emisphere's Eligen (R) oral drug delivery technology. Drug Dev 2004; 4: 849.
  • 83
    Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med 2004; 21: 3547.
  • 84
    Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, Chou J, McDonough J, Baughman RA. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001; 18: 96470.
  • 85
    Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008; 84: 46874.
  • 86
    Emisphere. Press Release. Novo Nordisk starts phase I trial with long-acting oral GLP-1 analogue. 2010. Available at http://ir.emisphere.com/releasedetail.cfm?ReleaseID=437329 (last accessed 12 April 2012).
  • 87
    Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007; 104: 1506974.
  • 88
    Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J, Beglinger C. The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr 2011; 30: 52432.
  • 89
    Patel MM. Cutting-edge technologies in colon-targeted drug delivery systems. Expert Opin Drug Deliv 2011; 8: 124758.
  • 90
    Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract 2010; 64: 140214.